Financial Data and Key Metrics Changes - As of January 31, 2025, the company reported total revenue of $17.9 million for the twelve months ended, down from $22.6 million in the previous fiscal year [14] - The net loss for the fourth quarter of fiscal 2024 was $2.1 million, compared to a net loss of $1.4 million in the same quarter of the previous year [16] - Cash and cash equivalents decreased to $2.2 million as of January 31, 2025, from $3.2 million a year earlier [17] Business Line Data and Key Metrics Changes - Booked SaaS Annual Contract Value (ACV) was $14 million as of January 31, 2025, and increased to $14.6 million by April 30, 2025 [14][16] - SaaS revenue for the fourth quarter of fiscal 2024 was $3.1 million, representing 66% of total revenue, down from $3.4 million or 64% in the same quarter of the previous year [16] Market Data and Key Metrics Changes - The company experienced a churn of $700,000 primarily due to two clients lost to acquisitions [7] - The denial prevention functionality is expected to significantly enhance the financial impact of the eValuator platform, potentially increasing inpatient financial impact by over 15% and doubling the impact on outpatient cases [10] Company Strategy and Development Direction - The company has decided to discontinue selling its quality module as an independent unit to focus resources on initiatives that expand the core value proposition [9] - The launch of the denial prevention functionality is seen as timely, addressing the surge in denial activity from commercial payers [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving an EBITDA profitable run rate during the first half of fiscal 2025 [14] - The company is focusing on enhancing client relationships and leveraging successful client stories to drive bookings [28] Other Important Information - The company amended certain financial covenants related to its senior term loan and revolving line of credit on March 28, 2025 [17] - The implementation timeline for eValuator has improved significantly, with recent implementations completed in as little as 42 days [26] Q&A Session Summary Question: Can you talk about the denials prevention product and its marketability? - Management highlighted the importance of integrating denial signals into the pre-bill workflow to enhance claim accuracy, which clients find immensely valuable [22][23] Question: What changes have enabled quicker implementations? - The company has standardized data and training processes, significantly reducing implementation times from four to six months to two to three months [27] Question: What gives confidence in building momentum for bookings? - Management noted increased top-of-funnel activity driven by client success stories and recent events, indicating a positive trend in bookings [28][29]